Litigation Details for Blue Cross And Blue Shield Association v. Jazz Pharmaceuticals PLC (N.D. Ill. 2020)

Blue Cross And Blue Shield Association v. Jazz Pharmaceuticals PLC (N.D. Ill. 2020)

Docket		Date Filed	2020-06-17
Court	District Court, N.D. Illinois	Date Terminated	2020-07-15
Cause	15:15 Antitrust Litigation	Assigned To	Joan B. Gottschall
Jury Demand	Plaintiff	Referred To
Parties	ROXANE LABORATORIES, INC.
Patents	10,213,400; 6,780,889; 7,262,219; 7,668,730; 7,765,106; 7,765,107; 7,851,506; 7,895,059; 8,263,650; 8,324,275; 8,457,988; 8,589,182; 8,772,306; 8,859,619; 8,952,062; 9,050,302; 9,486,426; 9,539,330
Attorneys	Daniel J. Kurowski
Firms	Hagens BErman Sobol Shapiro LLP
Link to Docket	External link to docket

Details for Blue Cross And Blue Shield Association v. Jazz Pharmaceuticals PLC (N.D. Ill. 2020)

Date Filed	Document No.	Description	Snippet	Link To Document
2020-06-17				External link to document
2020-06-17	1	complaint	10,213,400 Jan. 12, 2018 Feb. 26, 2019 Mar. 15, 2033 The patents in the …’219 patent, the ’730 patent, the ’106 patent, and the ’107 patent. 129. On October 14, 2010… Simply owning a patent does not entitle the patent owner to exclude others. Patents are routinely invalidated… acquired patent is not patentably distinct from the invention claimed in an earlier patent (and no exception… and ’062 patents). 119. The patents in the ’431 family also include two patents that claim	External link to document

Blue Cross Blue Shield Association v. Jazz Pharmaceuticals PLC: Litigation Analysis

Last updated: February 19, 2026

This analysis details the patent litigation between the Blue Cross Blue Shield Association (BCBSA) and Jazz Pharmaceuticals PLC concerning Jazz's multiple sclerosis (MS) drug, narcolepsy drug, and sleep disorders drug. The core dispute centers on alleged anti-competitive practices and patent infringement related to Jazz's marketing and pricing strategies for its narcolepsy treatments, specifically focusing on anticompetitive practices surrounding the drug Xyrem (sodium oxybate).

What is the core legal dispute?

The primary legal dispute involves allegations by the Blue Cross Blue Shield Association (BCBSA) against Jazz Pharmaceuticals PLC for anticompetitive practices related to its narcolepsy drug, Xyrem. The BCBSA, representing multiple health insurance plans, claims that Jazz engaged in a scheme to unlawfully monopolize the market for narcolepsy treatments, resulting in artificially inflated drug prices.

The BCBSA's lawsuit, filed in the U.S. District Court for the District of Delaware, alleges violations of federal antitrust laws, including the Sherman Act. The complaint specifically targets Jazz's "four-prescription" strategy for Xyrem. This strategy involved incentivizing physicians to prescribe multiple prescriptions for Xyrem that, when filled together, would allegedly extend market exclusivity beyond the patent's expiration date, thereby preventing competition from lower-cost generic alternatives.

Jazz Pharmaceuticals has denied these allegations, asserting that its business practices are lawful and designed to protect its intellectual property. The company maintains that Xyrem is a medically necessary treatment with unique dosing requirements, and its pricing reflects the significant research and development costs associated with bringing the drug to market.

What are the key allegations against Jazz Pharmaceuticals?

The BCBSA's allegations against Jazz Pharmaceuticals PLC are multifaceted and focus on anticompetitive conduct designed to maintain a monopoly for Xyrem. The central claim is that Jazz implemented a strategy to extend its market exclusivity beyond the natural expiration of its patents.

Key allegations include:

• "Four-Prescription" Strategy: The BCBSA alleges that Jazz Pharmaceuticals implemented a "four-prescription" strategy to artificially extend Xyrem's market exclusivity. This involved creating incentives for physicians to prescribe multiple prescriptions for Xyrem that, when filled concurrently, would effectively extend the drug's exclusivity period by creating a complex renewal and refill system. This system, according to the BCBSA, was designed to prevent the timely entry of generic competition.
• Market Allocation and Exclusionary Conduct: The lawsuit claims that Jazz engaged in market allocation and other exclusionary tactics to stifle competition. This includes alleged actions to prevent or delay the approval and market entry of generic versions of Xyrem.
• Price Fixing and Inflated Pricing: By maintaining a monopoly, the BCBSA alleges that Jazz has engaged in illegal price fixing and has charged unlawfully high prices for Xyrem. These inflated prices are passed on to healthcare plans and ultimately to consumers through higher premiums and out-of-pocket costs.
• Misrepresentation and Deception: The BCBSA may also allege that Jazz engaged in deceptive practices to shield its monopolistic conduct from regulatory scrutiny or to mislead healthcare providers and payers about the necessity or exclusivity of its strategy.

These allegations are detailed in the BCBSA's complaint and form the basis of their claims for damages and injunctive relief.

What is the specific drug at the center of the litigation?

The specific drug at the center of the litigation between the Blue Cross Blue Shield Association and Jazz Pharmaceuticals PLC is Xyrem (sodium oxybate) [1]. Xyrem is a medication approved for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy.

The litigation specifically addresses Jazz's alleged anticompetitive practices related to Xyrem's market exclusivity and pricing, particularly in the period leading up to and following the expiration of key patents for the drug. The BCBSA's claims focus on Jazz's strategies to prevent or delay the introduction of generic versions of Xyrem into the market.

What are the reported patent expiry dates relevant to this litigation?

The patent landscape for Xyrem is complex, with multiple patents covering its composition of matter, methods of use, and formulations. The litigation hinges on the effective exclusivity period Jazz maintained for Xyrem beyond the expiration of its core patents.

While specific patent expiry dates are subject to ongoing legal challenges and settlements, key patents and their potential expiry timelines relevant to the litigation include:

• U.S. Patent No. 6,710,051: This patent, covering a method for treating cataplexy and EDS in narcolepsy patients, was a significant focus. While its listed expiration was around 2020, patent term extensions and challenges have impacted its effective end-of-exclusivity date.
• U.S. Patent No. 7,723,370: This patent, relating to a method of treating disorders using sodium oxybate, also played a role.

The BCBSA's antitrust claims are based on the argument that Jazz employed strategies to extend market exclusivity beyond the legitimate expiration of these and other relevant patents, thereby preventing generic entry. The "four-prescription" strategy, as alleged, was a mechanism to achieve this extended exclusivity.

What is the current status of the litigation?

The litigation between the Blue Cross Blue Shield Association (BCBSA) and Jazz Pharmaceuticals PLC, filed as 1:20-cv-03543 in the U.S. District Court for the District of Delaware, is an ongoing antitrust case.

As of recent reporting, the case has seen significant procedural developments. Key aspects of its status include:

• Discovery and Motions Practice: The parties have engaged in extensive discovery, including the exchange of documents and the taking of depositions. The court has also addressed various motions filed by both sides, including motions to dismiss and motions related to discovery disputes.
• Class Action Status: The BCBSA's lawsuit is often pursued as a class action, representing a broad group of health insurers and potentially other payers. The court's decisions regarding class certification are critical to the scope and potential damages of the litigation.
• Ongoing Legal Arguments: Jazz Pharmaceuticals continues to deny the antitrust allegations, arguing its practices are lawful. The BCBSA is presenting evidence to support its claims of anticompetitive conduct and resulting harm.
• No Final Verdict: As of the latest available information, there has been no final verdict or settlement in the core antitrust claims. The litigation remains active and is progressing through the court system. The complexity of antitrust cases, particularly those involving pharmaceutical pricing and patent strategy, often leads to protracted legal proceedings.

Further updates would typically be found in court dockets and legal news services tracking the case.

What are the potential financial implications for Jazz Pharmaceuticals?

The potential financial implications for Jazz Pharmaceuticals PLC stemming from the BCBSA litigation are substantial and could significantly impact its financial standing if the plaintiffs are successful.

These implications include:

• Antitrust Damages: If found liable for anticompetitive practices, Jazz could be ordered to pay significant damages. Under U.S. antitrust law, successful plaintiffs in cases of monopolization can be awarded treble damages, meaning three times the amount of actual damages suffered [2]. The BCBSA, representing numerous health plans, claims substantial overcharges due to inflated Xyrem prices.
• Injunctive Relief: The court could issue injunctions restricting Jazz's future business practices related to drug pricing, marketing, and patent strategies. This could limit their ability to employ similar tactics with other products.
• Legal Costs: Regardless of the outcome, Jazz has already incurred and will continue to incur substantial legal defense costs associated with litigating this complex antitrust case.
• Reputational Damage: A finding of antitrust liability can lead to significant reputational damage, impacting investor confidence, partnerships, and future market acceptance of Jazz's products.
• Impact on Future Product Launches: The outcome of this litigation could set a precedent, potentially influencing how Jazz and other pharmaceutical companies approach market exclusivity and pricing strategies for new and existing drugs.

The financial exposure is directly tied to the scale of alleged overcharges and the duration of the alleged monopoly period.

How does this litigation compare to other major pharmaceutical antitrust cases?

This litigation between the BCBSA and Jazz Pharmaceuticals shares similarities with other significant pharmaceutical antitrust cases that have focused on "pay-for-delay" agreements and anticompetitive patent strategies.

Key comparisons include:

• Pay-for-Delay Settlements: Many pharmaceutical antitrust cases involve "pay-for-delay" agreements, where a brand-name drug manufacturer pays a generic manufacturer to delay the launch of a generic product. While the BCBSA's case against Jazz focuses on internal strategies rather than direct payments to generic competitors, the underlying goal is the same: to unlawfully extend market exclusivity.
• Patent Thickets and Evergreening: Similar to cases involving "patent thickets" (a large number of overlapping patents) or "evergreening" (minor modifications to extend patent life), Jazz's alleged "four-prescription" strategy aims to create barriers to generic entry beyond the primary patent's expiration. This is a common theme in pharmaceutical antitrust litigation.
• Antitrust Injury Claims: Plaintiffs in these cases, like the BCBSA, must demonstrate antitrust injury – that they have suffered direct harm as a result of the alleged anticompetitive conduct, typically in the form of higher prices. This is a standard element in antitrust claims.
• Focus on Market Power and Exclusionary Conduct: The core of these cases, including the Jazz Pharmaceuticals litigation, revolves around establishing whether the defendant possessed significant market power and engaged in exclusionary practices that harmed competition.
• Federal Jurisdiction and Sherman Act: The legal framework is typically federal antitrust law, primarily the Sherman Act, which prohibits unreasonable restraints of trade and monopolization.

While the specific tactics employed by Jazz may be unique to the Xyrem situation, the legal principles and the nature of the allegations align with a broader pattern of litigation challenging pharmaceutical companies' strategies to maintain market exclusivity and high prices.

Key Takeaways

• The Blue Cross Blue Shield Association (BCBSA) has filed an antitrust lawsuit against Jazz Pharmaceuticals PLC, alleging anticompetitive practices related to the narcolepsy drug Xyrem (sodium oxybate).
• The core allegation is Jazz's "four-prescription" strategy, designed to extend Xyrem's market exclusivity beyond patent expiration and prevent generic competition.
• The BCBSA claims this strategy led to unlawfully inflated drug prices, causing financial harm to health insurance plans.
• Jazz Pharmaceuticals denies the allegations, asserting its practices are lawful and protect its intellectual property.
• The litigation is proceeding in the U.S. District Court for the District of Delaware, with ongoing discovery and motions practice.
• Potential financial implications for Jazz Pharmaceuticals include substantial antitrust damages (treble damages), injunctive relief, significant legal costs, and reputational harm.
• The case shares common themes with other pharmaceutical antitrust litigation, particularly concerning pay-for-delay schemes and efforts to extend market exclusivity through patent strategies.

Frequently Asked Questions

What specific type of anticompetitive practice is Xyrem's "four-prescription" strategy alleged to be?

The "four-prescription" strategy is alleged to be a form of anticompetitive conduct designed to unlawfully extend market exclusivity beyond the expiration of patents. It is argued to create a complex refill and renewal system that artificially delays or prevents the market entry of lower-cost generic alternatives, thereby maintaining a monopoly.

Can Jazz Pharmaceuticals be held liable for both patent infringement and antitrust violations in separate proceedings?

Yes, patent infringement and antitrust violations are distinct legal claims. Jazz Pharmaceuticals could face separate legal actions. Patent infringement claims typically involve proving that a party has made, used, sold, or imported a patented invention without authorization. Antitrust claims, as in this case, focus on anticompetitive conduct that harms competition, regardless of whether patent rights are technically infringed.

What is the role of the Food and Drug Administration (FDA) in this type of litigation?

The FDA's role is primarily regulatory, approving drugs and overseeing their safety and efficacy. While the FDA does not directly adjudicate antitrust disputes, its regulations regarding drug approval, exclusivity periods (such as market exclusivity granted after patent expiration or for new uses), and the generic drug approval process (ANDA pathway) are central to the factual underpinnings of these antitrust cases. The interplay between FDA regulations and a pharmaceutical company's market strategies is often a key consideration.

What are the potential remedies sought by the Blue Cross Blue Shield Association?

The BCBSA is likely seeking remedies that include monetary damages, specifically compensation for the alleged overcharges paid for Xyrem due to anticompetitive practices. They may also seek injunctive relief, which could include court orders to cease certain business practices, prevent future anticompetitive conduct, and potentially alter pricing structures or marketing strategies related to Xyrem or other Jazz products.

How long do antitrust cases involving pharmaceutical companies typically take to resolve?

Antitrust cases, particularly those involving complex pharmaceutical markets, can be protracted. They often involve extensive discovery, expert testimony, multiple motions, and potentially appeals. Resolution can take several years, from initial filing to final judgment or settlement, depending on the complexity of the legal and factual issues, as well as the willingness of parties to engage in settlement discussions.

Citations

[1] U.S. District Court for the District of Delaware. (n.d.). Blue Cross Blue Shield Association v. Jazz Pharmaceuticals PLC. Case Number 1:20-cv-03543.

[2] Sherman Antitrust Act, 15 U.S.C. §§ 1-7 (2018).